 Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2VEGFR-2 tyrosine kinase inhibitor TKI. The investigators have finished the preclinical,phase I and phase II clinical studies and found its promising anti-tumor activity and tolerable toxicities. A disease-control rate of 61.1 and a mPFS of 4.7 months were showed in apatinib phase II study in patients with NSCLC. 